Contemporary practice patterns of stereotactic radiosurgery for brain metastasis: A review of published Australian literature.
brain metastasis
stereotactic radiosurgery
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
08
01
2019
accepted:
29
07
2019
pubmed:
30
8
2019
medline:
11
3
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
There has been a shift in the management of brain metastasis (BM), with increasing use of stereotactic radiosurgery (SRS) and delaying/avoiding whole-brain radiotherapy (WBRT), given the concern regarding the long-term neurocognitive effect and quality of life impact of WBRT. It is, however, unclear as to the contemporary practice pattern and outcomes of SRS in Australia. We conducted a literature search in PubMed and MEDLINE using a series of keywords: 'stereotactic', 'radiosurgery' and 'brain metastases', limiting to Australian studies, which report on clinical outcomes following SRS. Eight studies - one randomized trial and seven retrospective cohort studies - were identified and included in this review. A total of 856 patients were included, with the most common primary tumour types being melanoma, lung cancer and breast cancer. Approximately half of the patients had solitary BM, while 7% had 10 or more BM lesions. SRS is not routinely given in combination with WBRT. The 6-month intracranial control and 1-year intracranial control following SRS were reported in the range of 67-87% and 48-82%, respectively, whereas the 1-year overall survival and 2-year overall survival were reported in the range of 37-60% and 20-36%, respectively. There are limited data reported on SRS-related toxicities in all included studies. Overall, despite increasing use of SRS for BM, there is a low number of published Australian series in the literature. There is a potential role for establishing an Australian clinical quality registry or collaborative consortium for SRS in BM, to allow for systematic prospective data collection, and benchmarking of quality and outcomes of SRS.
Identifiants
pubmed: 31464070
doi: 10.1111/1754-9485.12942
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-720Subventions
Organisme : AVANT Doctor-in-Training Grant
Informations de copyright
© 2019 The Royal Australian and New Zealand College of Radiologists.
Références
Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 2011; 22: 1-6, v.
Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29: 134-41.
Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-91.
Kayama T, Sato S, Sakurada K et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol 2018; 36: 3282-9.
Brown PD, Ballman KV, Cerhan JH et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC. 3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1049-60.
Brown PD, Jaeckle K, Ballman KV et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016; 316: 401-9.
Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10: 1037-44.
Soffietti R, Kocher M, Abacioglu UM et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013; 31: 65-72.
Royal Australia and New Zealand College of Radiologists. Five Things Clinicians and Consumers Should Question. [Cited 1 February 2019]. Available from URL: http://www.choosingwisely.org.au/getmedia/041eb540-e46d-434a-87c4-640991c7dd87/CW_Recommendations_RANZCR_combined_20170410.pdf.aspx.
Ong WL, Foroudi F, Milne RL, Millar JL. Are we choosing wisely in radiation oncology practice-findings from an Australian population-based study. Int J Radiat Oncol Biol Phys 2019; 104: 1012-6.
Roos DE, Smith JG, Stephens SW. Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomised controlled trial. Clin Oncol (R Coll Radiol) 2011; 23: 646-51.
Roos DE, Brophy BP, Bhat MK, Katsilis ES. Update of radiosurgery at the Royal Adelaide Hospital. Australas Radiol 2006; 50: 158-67.
Sia J, Paul E, Dally M, Ruben J. Stereotactic radiosurgery for 318 brain metastases in a single Australian centre: the impact of histology and other factors. J Clin Neurosci 2015; 22: 303-7.
Croker J, Chua B, Bernard A, Allon M, Foote M. Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy. Clin Exp Metastasis 2016; 33: 125-32.
Nicholls LW, Pinkham MB, Bernard A et al. Radiological kinetics of brain metastases and clinical implications for patients treated with stereotactic radiosurgery. Clin Oncol (R Coll Radiol) 2019; 31: 34-40.
Choong ES, Lo S, Drummond M et al. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer 2017; 75: 169-78.
Izard MA, Moutrie V, Rogers JM et al. Volume not number of metastases: Gamma Knife radiosurgery management of intracranial lesions from an Australian perspective. Radiother Oncol 2019; 133: 43-9.
Or M, Jayamanne D, Guo L et al. Focal radiation therapy for limited brain metastases is associated with high rates of local control and low subsequent whole brain radiation therapy. ANZ J Surg 2019; 89: 418-22.
McTyre E, Ayala-Peacock D, Contessa J et al. Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis. Ann Oncol 2018; 29: 497-503.
Farris M, McTyre ER, Cramer CK et al. Brain metastasis velocity: a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone. Int J Radiat Oncol Biol Phys 2017; 98: 131-41.
Ayala-Peacock DN, Peiffer AM, Lucas JT et al. A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro Oncol 2014; 16: 1283-8.
Fogarty G, Morton RL, Vardy J et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer 2011; 11: 142.
Fogarty G, Dolven-Jacobsen K, Morton R et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). J Clin Oncol 2019; 37: 9500.
Gabani P, Fischer-Valuck BW, Johanns TM et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol 2018; 128: 266-73.
Diao K, Bian SX, Routman DM et al. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 2018; 139: 421-9.
Lu VM, Goyal A, Rovin RA, Lee A, McDonald KL. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol 2019; 141: 1-12.
Verduin M, Zindler JD, Martinussen HM et al. Use of systemic therapy concurrent with cranial radiotherapy for cerebral metastases of solid tumors. Oncologist 2017; 22: 222-35.
Routman DM, Yan E, Vora S et al. Preoperative stereotactic radiosurgery for brain metastases. Front Neurol 2018; 9: 959.
Patel KR, Burri SH, Asher AL et al. Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery 2016; 79: 279-85.
Siva S, Louie AV, Warner A et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 2018; 124: 934-42.